THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 111 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $408,000 | -65.0% | 45,000 | -63.1% | 0.10% | -57.2% |
| Q1 2022 | $1,166,000 | +709.7% | 122,000 | +838.5% | 0.23% | +748.1% |
| Q4 2021 | $144,000 | +50.0% | 13,000 | 0.0% | 0.03% | +35.0% |
| Q3 2021 | $96,000 | -71.3% | 13,000 | -43.5% | 0.02% | -70.6% |
| Q2 2021 | $334,000 | -28.8% | 23,000 | 0.0% | 0.07% | -35.2% |
| Q1 2021 | $469,000 | +14.7% | 23,000 | 0.0% | 0.10% | +9.4% |
| Q4 2020 | $409,000 | +20.3% | 23,000 | 0.0% | 0.10% | +9.1% |
| Q3 2020 | $340,000 | -29.6% | 23,000 | 0.0% | 0.09% | -38.0% |
| Q2 2020 | $483,000 | +41.2% | 23,000 | +55.4% | 0.14% | -4.1% |
| Q1 2020 | $342,000 | -41.3% | 14,800 | -34.2% | 0.15% | -3.9% |
| Q4 2019 | $583,000 | +71.0% | 22,500 | +28.6% | 0.15% | +57.1% |
| Q3 2019 | $341,000 | -14.8% | 17,500 | -28.6% | 0.10% | -18.3% |
| Q2 2019 | $400,000 | +3.9% | 24,500 | +44.1% | 0.12% | 0.0% |
| Q1 2019 | $385,000 | – | 17,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |